Flomics Biotech joins Eurostars project LUMINA to advance lung cancer recurrence detection using liquid biopsy and AI
The project, which launched on June 1, 2025, aims to develop an innovative platform for the non-invasive detection of minimal residual disease (MRD) in lung cancer patients using multi-omic biomarkers and artificial intelligence algorithms.
Minimal residual disease remains a major challenge in oncology. In lung cancer, up to 60% of patients treated with curative intent experience a relapse. The LUMINA project seeks to address this unmet need by analysing liquid biopsies, integrating circulating RNA and DNA biomarkers with advanced predictive models to identify disease progression before it becomes clinically or radiologically evident.
Flomics contributes its unique expertise in total RNA analysis for liquid biopsy applications, a field where the company has established itself as a leader. Its technology enables the detection of complex molecular signatures that complement DNA-based analyses, thereby enhancing the platform's sensitivity and specificity. Combined with machine learning tools developed by consortium leader RenovaroCube, this multi-omic approach could redefine clinical standards for post-treatment monitoring.
The consortium also includes Uppsala University, a European leader in biomedical research, and Oncodia AB, a Swedish company specializing in molecular diagnostic products. Flomics' activities in LUMINA are supported by a €619k grant from the CDTI. This milestone strengthens Flomics' position as a key player in advanced RNA-based diagnostics and reaffirms its commitment to precision medicine.
